CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Nebivololdrug
Likely dose
Nebivolol 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01202175
NCT01202175Phase 4Completed
CompareCT.gov

Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.

University of California, San Diego·interventional·Posted Sep 15, 2010·Updated Aug 21, 2019

In Brief

A Phase 4 clinical trial evaluating Nebivolol for Pre-hypertension and Hypertension. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The investigators aim to evaluate subjects at high risk of future development of hypertension, those with a family history of hypertension and/or that already have high normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to investigate whether these subjects have the same markers (such as microscopic protein in the urine or C-reactive protein in the blood) in the blood and urine that people with high blood pressure have, and whether they are improved before and after taking the beta-blocker nebivolol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre-hypertension, Hypertension
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2010
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.8 years ago

Interventions

Nebivololdrug

Oral nebivolol 2.5-5mg once daily